ELVN (Enliven Therapeutics Inc) Earnings per share for the last four quarters

Public company logo of Enliven Therapeutics Inc (ELVN)

The EPS YoY TTM shift metric on GURU.Markets demonstrates profit dynamics, where 8.00 is the current value of the indicator. Enliven Therapeutics (ELVN) relies on solid capital, which ensures balance sheet stability. However, a narrow specialization in small molecules creates risks due to dependence on testing. In a fierce race for molecular precision, the success of third-party developments could become a critical challenge.

ELVN enliventherapeutics.com Earnings per share for the last twelve months (02/11/2024 - 11/18/2026)

Enliven Therapeutics Inc - analytical breakdowns and key metrics (ELVN)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:Enliven Therapeutics, Inc. (ELVN)
Signature product of Enliven Therapeutics, Inc.

EPS TTM dynamics reflect the rate of change in net income per share over the year, allowing investors to assess value generation efficiency and business model sustainability. For the pre-commercial developer Enliven Therapeutics (ELVN), where R&D cost growth outpaces revenues, measuring the annual EPS TTM growth reveals a lack of operating leverage, confirming the high capital intensity of the clinical trial stage.

Competitor analysis for Enliven Therapeutics

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ideayabio.com|Earnings per share for the last twelve months ORIC Pharmaceuticals, Inc. (ORIC)|RLAY (Relay Therapeutics, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics Inc)|Net earnings per share for the trailing year Tyra Bio|Verastem Oncology - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Therapeutics, Inc.|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX